So I have always heard that the company being mum about the new formulation was for competitive reasons. Maybe that is the reason but maybe not. I would have thought that if they truly have the plans that you outline, that spelling that out publicly might have gotten the Generics to pull back a bit and possibly be more amenable to striking some deal with Amarin if this plan of yours would truly wipe them out in the future. I am definitely not banking on anything until I hear something concrete from the company, and obviously the market isn’t either.
Market Data 
Markets 
AI
